Next 10 |
2024-03-22 06:49:48 ET Summary BridgeBio Pharma has submitted a New Drug Application (NDA) for acoramidis, a potential treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), to the FDA and a Marketing Authorisation Application (MAA) to the EMA. The company has made deals wi...
2024-03-20 22:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-06 05:59:59 ET Read the full article on Seeking Alpha For further details see: BridgeBio prices $250M stock offering
- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiered structure beginning in the low-thirties percent, designed to provide Br...
2024-02-29 06:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-15 09:12:07 ET More on Alnylam Pharmaceuticals Alnylam's Huge Opportunity Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Alnylam Pharmaceuticals Q4 2023 Earnings Preview Investors growing more bullish on SMID cap biotech stocks S...
2024-02-07 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-07 10:37:54 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Pharma granted FDA review f...
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive upfront payment of USD 100 million with royalties up to the high-twenties percent, with additional milestone-based payments - Infigr...
2024-02-05 07:56:15 ET More on BridgeBio Pharma BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner BridgeBio Pharma: Taking Some Profits BridgeBio Pharma inks royalty deal fo...
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
2024-03-20 22:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage biopharmaceutical c...
Monday, BridgeBio Pharma Inc (NASDAQ:BBIO) and Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced a partnership wherein BridgeBio grant...